Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLACNASDAQ:CHEKNASDAQ:NAYANASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLACBellevue Life Sciences Acquisition$1.21+5.3%$1.52$3.01▼$13.40$12.16M-0.0819,293 shs1.22 million shsCHEKCheck-Cap$0.85-0.5%$0.79$0.56▼$3.04$4.96M0.21378,690 shs7,217 shsNAYANAYA Biosciences$1.78-9.0%$2.05$1.38▼$17.04$1.19M2.0353,151 shs289,797 shsQNRXQuoin Pharmaceuticals$8.90+5.1%$7.41$5.01▼$54.95$5.23M1.39135,865 shs27,522 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLACBellevue Life Sciences Acquisition+7.08%+6.14%-9.02%-71.33%-88.72%CHEKCheck-Cap-0.53%-8.38%+25.94%+11.23%-62.16%NAYANAYA Biosciences-8.95%-9.18%-7.29%-60.99%+177,999,900.00%QNRXQuoin Pharmaceuticals+5.08%+15.58%+35.67%-20.36%-66.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACHEKCheck-Cap0.5569 of 5 stars0.05.00.00.00.70.00.6NAYANAYA BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AQNRXQuoin Pharmaceuticals0.1343 of 5 stars0.03.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLACBellevue Life Sciences Acquisition 0.00N/AN/AN/ACHEKCheck-Cap 0.00N/AN/AN/ANAYANAYA Biosciences 3.00Buy$24.001,248.31% UpsideQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/AN/ACHEKCheck-CapN/AN/AN/AN/A$4.05 per shareN/ANAYANAYA Biosciences$6.23M0.19N/AN/A($2.06) per share-0.86QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLACBellevue Life Sciences AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ACHEKCheck-Cap-$17.57M-$3.00N/A∞N/AN/AN/AN/A6/3/2025 (Estimated)NAYANAYA Biosciences-$8.03MN/A0.00∞N/A-119.91%N/A-41.72%6/29/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.69M-$48.81N/AN/AN/AN/A-125.60%-64.77%N/ALatest NAYA, CHEK, QNRX, and BLAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/A3/13/2025Q4 2024QNRXQuoin Pharmaceuticals-$17.50-$12.25+$5.25-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLACBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/ACHEKCheck-CapN/AN/AN/AN/AN/ANAYANAYA BiosciencesN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLACBellevue Life Sciences AcquisitionN/AN/AN/ACHEKCheck-CapN/A19.67N/ANAYANAYA BiosciencesN/A0.230.20QNRXQuoin PharmaceuticalsN/A3.023.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLACBellevue Life Sciences Acquisition55.30%CHEKCheck-Cap1.07%NAYANAYA Biosciences12.02%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipBLACBellevue Life Sciences Acquisition33.67%CHEKCheck-Cap0.48%NAYANAYA Biosciences1.79%QNRXQuoin Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLACBellevue Life Sciences AcquisitionN/A4.04 million2.68 millionNot OptionableCHEKCheck-Cap805.85 million5.82 millionNot OptionableNAYANAYA Biosciences10666,0004.40 millionN/AQNRXQuoin Pharmaceuticals4588,0004.86 millionNot OptionableNAYA, CHEK, QNRX, and BLAC HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical StudyMay 22 at 11:14 AM | manilatimes.netQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeMay 20, 2025 | globenewswire.comQuoin reports progress in pediatric skin disorder studyMay 15, 2025 | investing.comQuoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 14, 2025 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial ResultsMay 14, 2025 | manilatimes.netA Peek at Quoin Pharmaceuticals's Future EarningsMay 12, 2025 | benzinga.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleMay 1, 2025 | finanznachrichten.deQuoin Pharmaceuticals regains Nasdaq compliance with bid priceMay 1, 2025 | investing.comQuoin Pharmaceuticals regains Nasdaq complianceApril 30, 2025 | msn.comQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleApril 30, 2025 | globenewswire.comWhy Quoin Pharmaceuticals, Ltd.’s (QNRX) Stock Is Down 13.50%April 10, 2025 | aaii.comQuoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignApril 10, 2025 | globenewswire.comQuoin Pharmaceuticals Ltd – ADR trading halted, news pendingApril 9, 2025 | markets.businessinsider.comQuoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirementsApril 6, 2025 | uk.investing.comQuoin announces additional data from Pediatric Netherton Syndrome studyApril 3, 2025 | markets.businessinsider.comQuoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for DosingApril 2, 2025 | reuters.comQuoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric PatientApril 2, 2025 | globenewswire.comQuoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesMarch 25, 2025 | globenewswire.comQNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26March 18, 2025 | msn.comQuoin Pharmaceuticals reports Q4 EPS (35c) vs ($2.08) last yearMarch 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAYA, CHEK, QNRX, and BLAC Company DescriptionsBellevue Life Sciences Acquisition NASDAQ:BLAC$1.21 +0.06 (+5.25%) As of 05/22/2025Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.Check-Cap NASDAQ:CHEK$0.85 0.00 (-0.53%) Closing price 05/23/2025 03:51 PM EasternExtended Trading$0.85 +0.00 (+0.52%) As of 05/23/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.NAYA Biosciences NASDAQ:NAYA$1.78 -0.18 (-8.95%) As of 05/22/2025NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases and fertility. NAYA Biosciences, formerly known as INVO BIOSCIENCE, is based in SARASOTA, Fla.Quoin Pharmaceuticals NASDAQ:QNRX$8.90 +0.43 (+5.08%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$8.80 -0.10 (-1.11%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
